Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

palazestrant (OP-1250)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Olema Pharma

Drug class:

Estrogen receptor antagonist, Selective estrogen receptor degrader

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B	OP-1250 Sensitive: B - Late Trials OP-1250 Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + OP-1250 Sensitive: C3 – Early Trials palbociclib + OP-1250 Sensitive : C3	palbociclib + OP-1250 Sensitive: C3 – Early Trials palbociclib + OP-1250 Sensitive : C3
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D
ER Y537S	Breast Cancer	ER Y537S	Breast Cancer	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	HER2 inhibitor + OP-1250 Sensitive: D – Preclinical HER2 inhibitor + OP-1250 Sensitive : D	HER2 inhibitor + OP-1250 Sensitive: D – Preclinical HER2 inhibitor + OP-1250 Sensitive : D
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	palbociclib + OP-1250 Sensitive: D – Preclinical palbociclib + OP-1250 Sensitive : D	palbociclib + OP-1250 Sensitive: D – Preclinical palbociclib + OP-1250 Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D	OP-1250 Sensitive: D – Preclinical OP-1250 Sensitive : D